Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
Cutaneous lupus erythematosus encompasses a spectrum of autoimmune skin conditions with characteristic photosensitive lesions requiring specialist diagnosis and management.
Cutaneous lupus erythematosus (CLE) is an autoimmune condition in which the immune system targets the skin, producing characteristic inflammatory lesions. CLE may occur as an isolated skin disease or as a manifestation of systemic lupus erythematosus (SLE). The relationship between cutaneous and systemic lupus varies by subtype; some forms of CLE carry a relatively low risk of systemic involvement, while others are closely associated with active SLE.
Three major subtypes of CLE are recognised: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus, of which discoid lupus erythematosus (DLE) is the most common form. Each subtype has distinct clinical features, prognostic implications, and associations with systemic disease. CLE is more prevalent in women and is frequently exacerbated by ultraviolet (UV) radiation.
Cutaneous lupus results from a dysregulated immune response in which autoreactive immune cells and autoantibodies cause inflammation and damage to the skin. UV radiation is the most important environmental trigger and can induce new lesions, exacerbate existing disease, or provoke systemic flares in patients with SLE. Strict photoprotection is therefore a cornerstone of management for all subtypes of CLE.
Additional risk factors and associations include:
The clinical features of CLE vary by subtype, but photosensitivity is a unifying feature across all forms.
ACLE is almost always associated with active SLE. The hallmark is the malar (butterfly) rash, a symmetrical erythematous eruption across the cheeks and bridge of the nose that characteristically spares the nasolabial folds. Generalised ACLE may present as a widespread photosensitive maculopapular eruption. ACLE lesions typically resolve without scarring.
SCLE presents as photodistributed, non-scarring lesions in one of two morphological patterns: annular polycyclic plaques with central clearing, or papulosquamous (psoriasiform) plaques. Lesions are most common on the upper trunk, shoulders, extensor arms, and dorsal hands. SCLE is strongly associated with anti-Ro/SSA antibodies and may be drug-induced. Approximately 10 to 15 percent of patients with SCLE meet criteria for SLE.
DLE is the most common form of chronic CLE and is characterised by well-defined, erythematous plaques with adherent scale, follicular plugging, and a tendency toward scarring and dyspigmentation. Key features include:
The diagnosis of CLE is based on clinical evaluation, histopathological examination, and serological testing. Dermoscopy can assist in the initial clinical assessment by revealing features such as follicular plugging, perifollicular whitish halos, and telangiectasia that support the diagnosis of DLE.
A skin biopsy is an important diagnostic tool. Routine histology demonstrates an interface dermatitis pattern with vacuolar degeneration of the basal layer, perivascular and periadnexal lymphocytic infiltrate, and basement membrane thickening. Direct immunofluorescence (the lupus band test) reveals granular deposition of immunoglobulins and complement at the dermal-epidermal junction in lesional skin.
Serological workup is recommended to assess for systemic involvement and includes antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-Ro/SSA and anti-La/SSB antibodies, complement levels (C3, C4), and a complete blood count. The extent of serological testing is guided by the clinical subtype and the suspicion for SLE.
The management of CLE is guided by the subtype, severity, and extent of disease, as well as the presence or absence of systemic involvement. Treatment aims to control active inflammation, prevent new lesion formation, and minimise scarring and dyspigmentation.
Rigorous photoprotection is the foundation of CLE management across all subtypes. Broad-spectrum sunscreen with an SPF of 50 or higher should be applied daily, along with sun-protective clothing, wide-brimmed hats, and avoidance of peak UV hours. Both UVA and UVB radiation can trigger or worsen CLE, and protection against both wavelengths is essential.
Topical corticosteroids are the first-line topical treatment for localised CLE. Medium- to high-potency preparations are used for body lesions, while lower-potency agents are preferred for the face. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) serve as effective steroid-sparing alternatives and are particularly useful for facial and periorbital lesions where prolonged corticosteroid use carries a higher risk of skin atrophy.
Hydroxychloroquine is the first-line systemic therapy for CLE and is effective across all subtypes. It has anti-inflammatory and immunomodulatory properties and is generally well tolerated for long-term use. Chloroquine or quinacrine may be added or substituted in patients who do not respond adequately to hydroxychloroquine alone. Regular ophthalmological monitoring is recommended during long-term antimalarial use to screen for retinal toxicity. Antimalarial therapy is managed through the prescription management programme at the Centre for Medical and Surgical Dermatology.
For patients with CLE that is refractory to antimalarials, second-line systemic options include methotrexate, mycophenolate mofetil, and dapsone. Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), is approved for SLE and may benefit patients with CLE in the context of systemic disease. Anifrolumab, targeting the type I interferon receptor, has also shown efficacy in SLE with skin involvement. These advanced therapies are available through the biologic and advanced small molecule therapy programme when indicated.
Medical evaluation is recommended for any new or persistent photosensitive skin rash, particularly if accompanied by scarring, hair loss, or dyspigmentation. Patients with known CLE should seek reassessment if lesions are worsening despite treatment, if new symptoms suggestive of systemic involvement develop (joint pain, oral ulcers, fatigue, unexplained fevers), or if scalp disease is causing progressive hair loss.
A referral from a family physician is the standard pathway to access dermatology services in Ontario. Dr. Maksym Breslavets at the Centre for Medical and Surgical Dermatology provides specialist evaluation and management of cutaneous lupus, including diagnostic biopsy, dermoscopy, and systemic therapy.
Your feedback helps us improve our condition information
A physician referral is required to access our medical services. Contact your primary care provider to begin the referral process.